In an exciting development for the biotechnology sector, one.bio, an innovative spinout from UC Davis, has successfully raised $27 million in funding to propel its groundbreaking work in the field of food and biopharmaceutical applications. This infusion of capital will enable one.bio to amplify its proprietary technology, which specializes in creating novel oligosaccharides derived from natural products. These unique ingredients are specifically designed to beneficially modulate the microbiome and enhance immune function—an area that holds tremendous potential for improving health outcomes across various demographics. With this new funding, one.bio aims to accelerate its research and development efforts, expand its product offerings, and ultimately bring its scientific breakthroughs to market more rapidly. The investment underscores strong confidence from investors in one.bio's mission to revolutionize how ingredients can promote gut health and immune resilience. As the team at one.bio continues to bridge the gap between innovative biotechnology and everyday applications, they are not only poised for growth but also for making a significant impact on nutritional products and therapeutic interventions. The funding will also support collaborations with research institutions and foster new partnerships, furthering one.bio's commitment to delivering scientifically validated solutions that align with consumer demand for health-conscious products. With this significant financial backing, one.bio is well-positioned to lead the charge in the next generation of biotechnology innovations.
Breaking Ground in Biotechnology: one.bio Secures $27M in Series A Funding Round
Recently funded · $27.0M Series aFood and Beverage
Get the full one.bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Aisot Technologies
Aisot Technologies is a Zurich-based AI company pioneering advanced, AI-driven investment solutions. Spun out of ETH Zurich in 2021, aisot leverages machine learning, large language models (LLMs), and quantitative methods to deliver precise, real-time investment insights. Its AI Insights Platform empowers asset managers, funds, family offices, and treasuries to anticipate market trends, optimize strategies, and mitigate risk. Recognized across Europe and the U.S., aisot partners with leading financial institutions to redefine quantitative investment management.
$2.5M Seed
today
Dognosis
Dognosis is a deep-tech startup in Bangalore decoding canine cognition to reveal the hidden world of scent. Our vision is a world where we have cracked the olfactory code of disease, making detecting disease as easy as breathing. Our mission is to save lives by detecting disease early and advance humanity towards truly proactive and preventative medicine. Our work revolves around increasing the bandwidth of human-canine collaboration, allowing us to catch the scent of disease at scale. Our first goal is to solve for early cancer detection by pioneering a multi-cancer breath-based test - BreathEasy - that will be ultra-affordable, highly accurate, and super accessible. We're always on the lookout for passionate and ambitious people to work with us. Feel free to say hi to woof@dognosis.tech
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
